Classification Antitubercular drug

Action/Kinetics: Inhibits DNA-de-pendent RNA polymerase in susceptible strains of Escherichia coli and Bacillus subtilis. Rapidly absorbed from the GI tract. Peak plasma levels after a single dose: 3 3 hr. Mean terminal tvi: 45 hr. About 85% is bound to plasma proteins. High-fat meals slow the rate, but not the extent, of absorption. About 30% of a dose is excreted in the feces and 53% in the urine, primarily as metabolites. The 25-O-desacetyl metabolite is equal in activity to rifabu-tin.

Uses: Prevention of disseminated Mycobacterium avium complex (MAC) disease in clients with advanced HIV infection. Contraindications: Hypersensitiv-ity to rifabutin or other rifamycins (e.g., rifampin). Use in clients with active tuberculosis. Lactation. Special Concerns: Safety and efficacy have not been determined in children, although the drug has been used in HIV-positive children. Side Effects: Oral: Taste perversion, discolored saliva (brownish-orange). GI: Anorexia, abdominal pain, diarrhea, dyspepsia, eructation, flatulence, N&V. Respiratory: Chest pain, chest pressure or pain with dyspnea. CNS: Insomnia, seizures, paresthesia, aphasia, confusion. Musculoskeletal: Asthenia, myalgia, arthralgia, myo-sitis. Body as a whole: Fever, headache, generalized pain, flu-like syndrome. Dermatologic: Rash, skin discoloration. Hematologic: Neutro-penia, leukopenia, anemia, eosino-philia, thrombocytopenia. Miscella neous: Discolored urine, nonspecific T wave changes on ECG, hepatitis, he-molysis, uveitis.

Drug Interactions: Rifabutin has liver enzyme-inducing properties and may be expected to have similar interactions as does rifampin. However, rifabutin is a less potent enzyme in-ducer than rifampin. How Supplied: Capsule: 150 mg

0 0

Post a comment